Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Payables (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Payables for 10 consecutive years, with $605.4 million as the latest value for Q4 2025.

  • Quarterly Payables rose 2.15% to $605.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $605.4 million through Dec 2025, up 2.15% year-over-year, with the annual reading at $605.4 million for FY2025, 2.15% up from the prior year.
  • Payables hit $605.4 million in Q4 2025 for Ascendis Pharma A, up from $592.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $605.4 million in Q4 2025 to a low of $76.0 million in Q4 2021.
  • Historically, Payables has averaged $385.7 million across 5 years, with a median of $539.8 million in 2023.
  • Biggest five-year swings in Payables: surged 369.59% in 2023 and later grew 2.15% in 2025.
  • Year by year, Payables stood at $76.0 million in 2021, then surged by 51.29% to $114.9 million in 2022, then soared by 369.59% to $539.8 million in 2023, then rose by 9.8% to $592.6 million in 2024, then grew by 2.15% to $605.4 million in 2025.
  • Business Quant data shows Payables for ASND at $605.4 million in Q4 2025, $592.6 million in Q4 2024, and $539.8 million in Q4 2023.